These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9360781)

  • 1. Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine?
    Storb R; Leisenring W; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan KM; Witherspoon R; Pettinger M; Bensinger W; Buckner CD; Clift R; Flowers ME; Hansen JA; Pepe M; Chauncey T; Sanders J; Thomas ED
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):194-201. PubMed ID: 9360781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
    Storb R; Pepe M; Anasetti C; Appelbaum FR; Beatty P; Doney K; Martin P; Stewart P; Sullivan KM; Witherspoon R
    Blood; 1990 Sep; 76(5):1037-45. PubMed ID: 2203481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival.
    Wagner JL; Seidel K; Boeckh M; Storb R
    Biol Blood Marrow Transplant; 2000; 6(6):633-9. PubMed ID: 11128814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J
    Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.
    Ruutu T; Volin L; Parkkali T; Juvonen E; Elonen E
    Blood; 2000 Oct; 96(7):2391-8. PubMed ID: 11001889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
    Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
    Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate.
    Kanda Y; Izutsu K; Hirai H; Sakamaki H; Iseki T; Kodera Y; Okamoto S; Mitsui H; Iwato K; Hirabayashi N; Furukawa T; Maruta A; Kasai M; Atsuta Y; Hamajima N; Hiraoka A; Kawa K
    Leukemia; 2004 May; 18(5):1013-9. PubMed ID: 15029208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis.
    Deeg HJ; Spitzer TR; Cottler-Fox M; Cahill R; Pickle LW
    Bone Marrow Transplant; 1991 Mar; 7(3):193-8. PubMed ID: 2059756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine alone vs cyclosporine plus methotrexate for post-transplant immunosuppression after HLA-identical sibling bone marrow transplantation: a randomized prospective study.
    Lee KH; Choi SJ; Lee JH; Kim S; Seol M; Lee YS; Kim WK; Lee JS; Lee JH
    Bone Marrow Transplant; 2004 Oct; 34(7):627-36. PubMed ID: 15300231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host disease after marrow transplantation.
    Storb R
    Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marrow transplant experience for children with severe aplastic anemia.
    Sanders JE; Storb R; Anasetti C; Deeg HJ; Doney K; Sullivan KM; Witherspoon RP; Hansen J
    Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
    Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A
    Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J; Ringdén O
    Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.